Smartphone app, blood test may predict clotting risk

By The Science Advisory Board staff writers
July 26, 2022

A team of researchers led by Dr. Kelly Michaelsen of the University of Washington is developing a test that could quickly and inexpensively determine prothrombin time/international normalized ratio (PT/INR) and clotting risk using a smartphone.

The test uses a smartphone's built-in vibration motor and camera to track movement of a copper particle in a drop of blood.

The developers will present the results of a study that describes their work on Wednesday in a Scientific Poster Session at AACC 2022.

The group tested blood from 140 anonymous patients at the University of Washington Medical Center in addition to blood from 79 patients with known blood-clotting issues.

In both groups, the new test produced results similar to those of laboratory PT/INR tests.

As a next step, Michaelsen is planning to research whether patients can use the new test by themselves at home. She envisions it being helpful for people in rural areas to minimize long and increasingly expensive trips to doctors.

The aim is to develop a test that will lead to more people spending more time in the desirable PT/INR range, which would mean they are not at risk for clots or uncontrolled bleeding.

People who take the blood-thinning medication warfarin to prevent blood clots that can lead to heart attacks need frequent blood testing to ensure that the drug is working. Currently, this testing occurs in a clinical laboratory or using expensive at-home testing systems; it involves a particular measure of the time it takes for a clot to form, PT, and calculating the INR so doctors can compare results between different tests or laboratories.

BrightInsight launches digital diagnostics platform at AACC
BrightInsight on Monday announced the launch of its digital Connected Diagnostics Platform at the 2022 AACC Annual Scientific Meeting and Clinical Lab...
LumiraDx to discuss microfluidic technology at AACC
LumiraDx announced that it will host an industry workshop at AACC 2022 on Wednesday, describing the impact of its microfluidic technology on lateral-flow...
Cytovale to present new data on rapid sepsis test at AACC
Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.
Companies announce new products ahead of AACC 2022
Several companies have announced the launch of laboratory diagnostic products in advance of AACC 2022.
DiaSorin nabs FDA clearance for infectious disease blood test
Saluggia, Italy-based DiaSorin on Friday announced that it has obtained U.S. Food and Drug Administration (FDA) clearance for the Liaison MeMed BV, its...

Copyright © 2022

Last Updated 7/26/2022 10:31:21 AM